Molecular pathways: targeting death receptors and smac mimetics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24824309.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2376.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibitor of apoptosis (IAP) proteins are overexpressed in multiple human malignancies, an event that is associated with poor prognosis and treatment resistance. Therefore, IAP proteins represent relevant targets for therapeutic intervention. Second mitochondrial activator of caspases (Smac) is a mitochondrial protein that is released into the cytosol upon the induction of programmed cell death and promotes apoptosis by neutralizing IAP proteins. On the basis of this property, a variety of small-molecule inhibitors have been developed that mimic the binding domain of the native Smac protein to IAP proteins. Evaluation of these Smac mimetics in preclinical studies revealed that they particularly synergize together with agents that trigger the death receptor pathway of apoptosis. Such combinations might therefore be of special interest for being included in the ongoing evaluation of Smac mimetics in early clinical trials.
Medical subject headings
- Biomimetic Materials
- Inhibitor of Apoptosis Proteins
- Intracellular Signaling Peptides and Proteins
- Mitochondrial Proteins
- Neoplasms
- Oligopeptides
- Receptors, Death Domain
- Signal Transduction